Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir

Antiviral Research

Volumn 96, Issue 3, 2012, Pages 376-385

  Dimmock, Nigel J ^a   Dove, Brian K ^b   Meng, Bo ^a   Scott, Paul D ^a   Taylor, Irene ^b   Cheung, Linda ^a   Hallis, Bassam ^b   Marriott, Anthony C ^a   Carroll, Miles W ^b   Easton, Andrew J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Defective interfering virus; Ferret; Influenza virus; Oseltamivir; Protection

Indexed keywords

244 DI RNA; ANTIVIRUS AGENT; OSELTAMIVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FERRET; GENE AMPLIFICATION; NONHUMAN; PRIORITY JOURNAL; RNA VIRUS; SERODIAGNOSIS; VIRUS INHIBITION; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DEFECTIVE VIRUSES; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MALE; NASAL LAVAGE FLUID; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; RNA, VIRAL; TRANSFECTION; WEIGHT LOSS;

INFLUENZA A VIRUS; MUS; MUSTELA; ORTHOMYXOVIRIDAE; RNA VIRUSES;

EID: 84869137361     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.09.017     Document Type: Article

References (64)

1. Barnard D.L. Animal models for the study of influenza pathogenesis and therapy. Antiviral Res. 2009, 82:A110-A120.
2. Barrett A.D.T., Dimmock N.J. Defective interfering viruses and infections of animals. Curr. Top. Microbiol. Immunol. 1986, 128:55-84.
3. Boltz D.A., Rehg J.E., McClaren J., Webster R.G., Govorkova E.A. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J. Infect. Dis. 2008, 197:1315-1323.
4. Cameron C.M., Cameron M.J., Bermejo-Martin J.F., Ran L., Xu L., Turner P.V., Ran R., Danesh A., Fang Y., Chan P.-K., M., Mytle N., Sullivan T.J., Collins T.L., Johnson M.G., Medina J.C., Rowe T., Kelvin D.J. Gene expression analysis of host innate immune responses during lethal H5N1 infection in ferrets. J. Virol. 2008, 82:11308-11317.
5. Childs R.A., Palma A.S., Wharton S., Matrosovich T., Liu Y., Chai W., Campanero-Rhodes M.A., Zhang Y., Eickmann M., Kiso M., Hay A., Matrosovich M., Feizi T. Receptor binding specificity of pandemic influenza A (H1N1) determined by carbohydrate microarray. Nat. Biotechnol. 2009, 27:797-799.
6. Colman P.M. New antivirals and drug resistance. Ann. Rev. Biochem. 2009, 78:95-118.
7. Cox N.J., Bridges C.B. Inactivated and live attenuated influenza vaccines in young children - how do they compare?. N. Engl. J. Med. 2007, 356:729-731.
8. Dimmock N.J. The biological significance of defective interfering viruses. Rev. Med. Virol. 1991, 1:165-176.
9. Dimmock N.J. Antiviral activity of defective interfering influenza virus in vivo. Viral and Other Infections of the Respiratory Tract 1996, 421-445. Chapman and Hall, London. S. Myint, D. Taylor-Robinson (Eds.).
10. Dimmock N.J., Beck S., McLain L. Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J. Gen. Virol. 1986, 67:839-850.
11. Dimmock N.J., Rainsford E.W., Scott P.D., Marriott A.C. Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral. J. Virol. 2008, 82:8570-8578.
12. Duan S., Boltz D.A., Seiler P., Li J., Bragstad K., Nielsen L.P., Webby R.J., Webster R.G., Govorkova E.A. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathogens 2010, 6:1001022.
13. Duesberg P.H. Distinct subunits of the ribonucleoprotein of influenza virus. J. Mol. Biol. 1969, 42:485-499.
14. Duhaut S.D., Dimmock N.J. Heterologous protection against a lethal human H1N1 influenza virus infection of mice by a H3N8 equine defective interfering virus: comparison of defective RNA sequences isolated from the DI inoculum and mouse lung. Virol. 1998, 248:241-253.
15. Duhaut S., Dimmock N.J. Approximately 150 nt from the 5' end of an influenza A virus segment 1 defective virion RNA are needed for genome stability during passage of defective virus in infected cells. Virol. 2000, 275:278-285.
16. Duhaut S.D., Dimmock N.J. Defective segment 1 RNAs that interfere with the production of infectious influenza virus require at least 150 nucleotides of 5' sequence. evidence from a plasmid-driven system. J. Gen. Virol. 2002, 83:403-411.
17. Duhaut S.D., Dimmock N.J. Defective influenza A virus generated entirely from plasmids: its RNA is expressed in infected mouse lung and modulates disease. J. Virol. Meth. 2003, 108:75-82.
18. Easton A.J., Scott P.D., Edworthy N.L., Meng B., Marriott A.C., Dimmock N.J. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo. Vaccine 2011, 29:2777-2784.
19. Francis T. Transmission of influenza by a filterable virus. Science 1934, 80:457-459.
20. Govorkova E.A., Ilyushina N.A., Boltz D.A., Douglas A., Yilmaz N., Webster R.G. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 2007, 51:1414-1424.
21. Govorkova E.A., Ilyushina N.A., Smith J., Webster R.G. Oseltamivir protects ferrets against lethal H5N1 influenza virus infection. Antiviral Res. 2006, 70:A29.
22. Govorkova E.A., Marathe B.M., Prevost A., Rehg J.E., Webster R.G. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. Antiviral Res. 2011, 91:81-88.
23. Guarner J., Falcon-Escobedo R. Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses. Arch. Med. Res. 2009, 40:655-661.
24. Hamelin M.-E., Baz M., Abed Y., Couture C., Joubert P., Beaulieu E., Bellerose N., Plante M., Mallett C., Schumer G., Kobinger G.P., Boivin G. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog. 2010, 6:1001015.
25. Hauge S.H., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 2009, 15:155-162.
26. Herlocher M.L., Elias S., Truscon R., Harrison S., Mindell D., Simon C., Monto A.S. Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. J. Infect. Dis. 2001, 184:542-546.
27. Herlocher M.L., Truscon R., Elias S., Yen H.L., Roberts N.A., Ohmit S.E., Monto A.S. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 2004, 190:1627-1630.
28. Holland J.J. Defective viral genomes. Virology 1990, 151-165. Raven Press, New York. second ed. B.N. Fields, D.M. Knipe (Eds.).
29. Holland J.J. Generation and replication of defective viral genomes. Virol. 1990, 77-99. Raven Press, New York. second ed. B.N. Fields, D.M. Knipe (Eds.).
30. Huang A.S., Baltimore D. Defective viral particles and viral disease processes. Nature (Lond.) 1970, 226:325-327.
31. Hurt A., Nor'e S.S., McCaw J.M., Fryer H.R., Mosse J., McLean A.R., Barr I.G. Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J. Virol. 2010, 84:9427-9438.
32. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., Muramoto Y., Tamura D., Sakai-Tagawa Y., Noda T., Sakabe S., Imai M., Hatta Y., Watanabe S., Li C., Yamada S., Fujii K., Murakami S., Imai H., Kakugawa S., Ito M., Takano R., Iwatsuki-Horimoto K., Shimojima M., Horimoto T., Goto H., Takahashi K., Makino A., Ishigaki H., Nakayama M., Okamatsu M., Takahashi K., Warshauer D., Shult P.A., Saito R., Suzuki H., Furuta Y., Yamashita M., Mitamura K., Nakano K., Nakamura M., Brockman-Schneider R., Mitamura H., Yamazaki M., Sugaya N., Suresh M., Ozawa M., Neumann G., Gern J., Kida H., Ogasawara K., Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1020-1025.
33. Ives J.A.L., Carr J.A., Mendel D.B., Tai C.Y., Lambkin R., Kelly L., Oxford J.S., Hayden F.G., Roberts N.A. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002, 55:307-317.
34. Jefferson T., Jones M., Doshi P., Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. Br. Med. J. 2009, 339.
35. Lee N., Chan P.K.S., Wong C.K., Wong K.-T., Choi K.-W., Joynt G.M., Lam P., Chan M.C.W., Wong B.C.K., Lui G.C.Y., Sin W.W.Y., Wong R.Y.K., Lam W.-Y., Yeung A.C.M., Leung T.F., So H.-Y., Yu A.X.Y., Sung J.J.Y., Hui D.S.C. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 infleunza A(H1N1) virus pneumonia. Antivir. Ther. 2011, 16:237-247.
36. Maines T., Jayaraman A., Belser J., Wadford D., Pappas C., Zeng H., Gustin K., Pearce M., Viswanathan K., Shriver Z., Raman R., Cox N., Sasisekharan R., Katz J., Tumpey T.M. Transmission and pathogenesis of swine-origin 2009 A (H1N1) influenza viruses in ferrets and mice. Science 2009, 325:484-487.
37. Mann A., Marriott A.C., Balasingam S., Lambkin R., Oxford J.S., Dimmock N.J. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine 2006, 24:4290-4296.
38. Matsuoka, Y., Lamirande, E.W., Subbarao, K., 2009. The ferret model for influenza. Current Protocols in Microbiology Chapter 15, Unit 15G.12.
39. Meijer A., Lackenby A., Hungnes O., Lina B., van der Werf S., Schweiger B., Opp M., Paget J., van de Kassteele J., Hay A., Zambon M., Scheme o.b.o.t.E.I.S. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 15:552-560.
40. Mendel D.B., Tai C.Y., Escarpe P.A., Li W., Sidwell R.W., Huffman J.H., Sweet C., Jakeman K.J., Merson J., Lacy S.A., Lew W., Williams M.A., Zhang L., Chen M.S., Bischofberger N., Kim C.U. Oral adminstration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 1998, 42:640-646.
41. Meng B., Marriott A.C., Dimmock N.J. The receptor preferences of influenza viruses. Influenza Other Respir. Viruses 2010, 4:147-153.
42. Morgan D.J., McLain L., Dimmock N.J. Protection of three strains of mice against lethal influenza in vivo by defective interfering virus. Virus Res. 1993, 29:179-193.
43. Munster V., de Wit E., van den Brand J.M.A., Herfst S., Schrauwen E.J.A., Bestebroer T.M., van de Vijver D., Boucher C.A., Koopmans M., Rimmelzwaan G.F., Kuiken T., Osterhaus A.D.M.E., Fouchier R.A.M. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009, 325:481-483.
44. Nayak D.P. Influenza virus defective interfering particles. Ann. Rev. Microbiol. 1980, 34:619-644.
45. Nayak D.P., Chambers T.M., Akkina R.K. Defective-interfering (DI) RNAs of influenza viruses: origin, structure, expression and interference. Curr. Top. Microbiol. Immunol. 1985, 114:103-151.
46. Nayak D.P., Chambers T.M., Akkina R.M. Structure of defective-interfering RNAs of influenza virus and their role in interference. The Influenza Viruses 1989, 269-317. Plenum Press, New York. R.M. Krug (Ed.).
47. Nichol K.L. Efficacy and effectiveness of influenza vaccination. Vaccine 2008, 26:D17-D22.
48. Noble S., Dimmock N.J. Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of type A influenza virus. J. Gen. Virol. 1994, 75:3485-3491.
49. Oxford J.S. Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza Other Respir. Viruses 2007, 1:27-34.
50. Perrault J. Origin and replication of defective interfering particles. Curr. Top. Microbiol. Immunol. 1981, 93:151-207.
51. Roux L., Simon A.E., Holland J.J. Effects of defective interfering viruses on viral replication and pathogenesis in vitro and in vivo. Adv. Virus Res. 1991, 40:181-211.
52. Scott P.D., Meng B., Marriott A.C., Easton A.J., Dimmock N.J. Defective interfering influenza virus confers only short-lived protection against influenza virus disease: evidence for a role for adaptive immunity in DI virus-mediated protection in vivo. Vaccine 2011, 29:6584-6591.
53. Scott P.D., Meng B., Marriott A.C., Easton A.J., Dimmock N.J. DI influenza A virus protects in vivo against disease caused by a heterologous influenza B virus. J. Gen. Virol. 2011, 92:2122-2132.
54. Shope R.E. Swine influenza. III Filtration experiments and etiology. J. Exp. Med. 1931, 54:373.
55. Smith J., Dutkowski R., Ward P. Antivirals for influenza in healthy adults. Lancet 2006, 367:1571.
56. Smith W., Andrewes C.H., Laidlaw P.P. A virus obtained from influenza patients. Lancet 1933, 2:66-68.
57. Smith H., Sweet C. Lessons for human influenza from pathogenicity studies with ferrets. Revs. Infect. Dis. 1988, 10:56-65.
58. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., Xu X., Lu X., Katz J., Cox N., Matsuoka Y. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate by plasmid-based reverse genetics. Virology 2003, 305:192-200.
59. Treanor J.J. Influenza vaccine - outmanoeuvring antigenic shift and drift. N. Engl. J. Med. 2004, 350:218-220.
60. Ujike M., Ejima M., Anraku A., Shimabukuro K., Obuchi M., Kishida N., Hong X., Takashita E., Fujisaki S., Yamashita K., Horikawa H., Kato Y., Oguchi A., Fujita N., Tashiro M., Odagiri T., Japan a.t.I.V.S.G.o. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Emerging Infect. Dis. 2011, 17:470-479.
61. van den Brand J.M.A., Stittelaar K.J., van Amerongen G., Rimmelzwaan G.F., Simon J., de Wit E., Munster V., Bestebroer T., Fouchier R.A.M., Kuiken T., Osterhaus A. Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J. Infect. Dis. 2010, 201:993-999.
62. von Magnus P. Incomplete forms of influenza virus. Adv. Virus Res. 1954, 21:59-79.
63. Ward P., Small I., Smith J., Suter P., Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 2005, 55(Suppl. S1):5-21.
64. Whitley R.J. Of ferrets and humans: influenza pathogenesis. J. Infect. Dis. 2010, 201:976-977.